Where does the long-term evidence actually hold up?
The clearest long-term human evidence for microbiome therapeutics is in preventing recurrent Clostridioides difficile infection (rCDI). A phase 2 open-label study of the rectal microbiome therapeutic RBX2660 followed patients for 24 months. Among those who had a successful response at 8 weeks, more than 90% remained free of CDI at 6, 12, and 24 months [3]. That means the benefit didn't fade—it held steady for two years. The study also showed that the gut microbiome shifted from a dysbiotic (unhealthy) state to a more diverse, healthy composition within 7 days of treatment, and that change remained stable through the entire 2-year follow-up [3].
Other microbiome products for C. diff also show strong short-term results that suggest long-term durability, though with shorter follow-up. For example, the oral capsule RBX7455 (a freeze-dried donor-derived product) prevented recurrence in 80–100% of patients across three dosing groups at 8 weeks, and that protection persisted through 6 months in responders [1]. Similarly, the defined bacterial consortium VE303 (8 carefully selected Clostridia strains) reduced recurrence to 13.8% versus 36.4% with placebo at 8 weeks in a phase 2 trial, and a phase 3 trial is now underway [1]. The pattern across these studies is consistent: when a microbiome therapeutic works for C. diff, the effect appears durable for at least 6 months to 2 years.
What about other diseases—is the long-term evidence there?
For conditions beyond C. diff, the long-term human evidence is much thinner. In liver disease, the most studied microbiome intervention is fecal microbiota transplant (FMT), but the data are mostly from small phase 1 or 2 trials with short follow-up. For example, in patients with hepatic encephalopathy (a brain complication of cirrhosis), FMT given by enema after antibiotics showed potential improvements in cognition and fewer hospitalizations in a phase 1 randomized trial, but the follow-up was limited [2]. In alcohol-related cirrhosis, FMT reduced short- and long-term consequences of alcohol use, but the sample sizes were small [2]. No large, multi-year trials have been completed for microbiome therapeutics in liver disease.
The review of microbiome therapeutics in liver disease explicitly states that 'future research is required in many areas before they are ready to use in patients' and that the most promising approaches—FMT, defined bacterial consortia, bacteriophages, and engineered probiotics—'should move forward to rigorous randomized clinical trials' [2]. That's a clear signal that long-term evidence doesn't yet exist for these applications. The same is true for metabolic fatty liver disease, where FMT trials have been 'largely unsuccessful in meaningfully changing clinical outcomes' [2]. So while the rationale is strong (the gut-liver axis is well-established), the long-term human proof is not there yet.
Is there long-term safety data?
Yes, and it's reassuring for C. diff treatments. In the 2-year RBX2660 study, no new adverse outcomes emerged during the entire follow-up period, and the safety profile was consistent with earlier, shorter studies [3]. For the oral capsule RBX7455, no significant treatment-related side effects were reported through 6 months [1]. And for the defined consortium VE303, fewer than half of recipients reported any side effect, most were mild gastrointestinal issues, and no treatment-related serious events or deaths occurred [1]. These are not huge numbers (the RBX2660 study was a phase 2 trial, not a massive post-market surveillance), but the pattern is consistent: when these products work, they appear safe in the medium term.
However, safety is not zero-risk. The review on liver disease notes one reported case of FMT transmitting a drug-resistant E. coli bloodstream infection to a patient with cirrhosis [2]. This highlights a key limitation of donor-derived products: they carry a small risk of transmitting pathogens. That's why the field is moving toward defined bacterial consortia (like VE303) that are manufactured from clonal cell banks, eliminating donor variability and reducing infection risk [1][5]. For those products, long-term safety data are still being collected, but the theoretical risk is lower.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2021 to 2024, 1 from 2024 or later, 5 in Q1 journals, collectively cited 388 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 50 papers retrieved from a database of over 500 million.
Sources used in this answer
Future Microbiome Therapeutics for Clostridioides difficile Infection
Reviews multiple live biotherapeutic products (LBPs) for C. diff, including RBX7455 (80–100% efficacy at 8 weeks, sustained through 6 months), VE303 (13.8% recurrence vs 36.4% placebo at 8 weeks in a phase 2 trial), and NTCD-M3 (5% recurrence vs 30% placebo in a phase 2b trial), noting that defined consortia offer standardized, safer alternatives to donor-derived FMT.
The Current and Future State of Microbiome Therapeutics in Liver Disease
Reviews microbiome therapeutics in liver disease, concluding that while FMT shows promise in small trials for hepatic encephalopathy and alcohol-related cirrhosis, long-term evidence from rigorous randomized trials is lacking, and most approaches (probiotics, FMT, defined consortia) are not yet ready for routine clinical use.
The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660
Reports 2-year follow-up data from a phase 2 open-label study of RBX2660 for recurrent C. diff: over 90% of treatment responders remained CDI-free at 6, 12, and 24 months, with gut microbiome restoration occurring within 7 days and remaining stable, and no new safety concerns emerged.
The long-term genetic stability and individual specificity of the human gut microbiome
Demonstrates that individual gut microbiomes are stable over 4 years (85% accuracy in identifying individuals from stool samples taken 4 years apart), and that specific microbial features are associated with cardiometabolic traits and plasma metabolites, supporting the rationale for durable microbiome-based therapies.
Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics
Reviews the landscape of artificial microbiome therapeutics (consortia, bacteriophages, metabolites, engineered probiotics), noting that these products promise safer, more reproducible effects than FMT but face major challenges in clinical positioning and regulatory approval.